Patent SG-11201811559W-A (SG)
Title: Cancer treatment combinations
Inventor: KIPPS THOMAS
IPC: A61K31/517
Filed: 2017-06-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1 Ill 11111 0 11101 010 11111 01 110 1 0 011101 11111 Ell Ell OHIO 11110 1111 OM Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2018/005519 A3 04 January 2018 (04.01.2018) WIP0 I PCT (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 31/517 (2006.01) A61K 31/41 (2006.01) HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, A61K 31/519 (2006.01) A61K 31/4162 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 39/395 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US2017/039536 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 27 June 2017 (27.06.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/355,171 27 June 2016 (27.06.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: THE REGENTS OF THE UNIVERSITY OF KM, ML, MR, NE, SN, TD, TG). CALIFORNIA [US/US]; 1111 Franklin Street, Twelfth Floor, Oakland, CA 94607 (US). Published: (72) Inventors: KIPPS, Thomas, J.; 13175 Caminito Mendio- — with international search report (Art. 21(3)) la, San Diego, CA 92130 (US). CHEN, Liguang; 12552 — before the expiration of the time limit for amending the San Bruno Cove, San Diego, CA 92130 (US). CUI, Bing; claims and to be republished in the event of receipt of 12642 Carmel Country Road, Unit 148, San Diego, CA amendments (Rule 48.2(h)) 92130 (US). — with sequence listing part of description (Rule 5.2(a)) Agent: JENKINS, Kenneth et al.; Mintz Levin Cohn Fer- (88) Date of publication of the international search report: (74) = ris Glovsky and Popeo, P.C., One Financial Center, Boston, 15 February 2018 (15.02.2018) MA 02111 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (81) Title: CANCER TREATMENT COMBINATIONS (54) FIG. 17C o 7.-J• c 0 0 0) .. k a ed i 0* A = A A M C:r ,-1 in in Cirmtuzumab 0 fl 10 10 mg/kg ibrutinib 0 5 0 .5 mg/kg 0 0 .- p - t -- (57) : There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering 1-1 to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further 0 el provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. 0 ., In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab. ..)